Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (‘AI’), epigenetics and genetics to improve cardiovascular disease prevention, detection and management… The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing.”
Cardio Diagnostics currently offers two clinical solutions, Epi+Gen CHD™ and PrecisionCHD™, as well as a population health and biopharma offerings, HeartRisk™ and CardioInnovate360™, respectively. Collectively, these solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care, from early detection and prevention to therapeutic development and population-level risk management. To view the full article, visit https://ibn.fm/Nfps9.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
The company’s approach addresses a critical gap in cardiovascular care: the need for earlier, more precise risk identification. Traditional risk assessment methods often miss individuals who go on to develop heart disease, while others may receive unnecessary treatments. By combining genetic and epigenetic data with AI, Cardio Diagnostics aims to provide tailored insights that can guide prevention and treatment strategies. This is particularly important given that cardiovascular disease remains the leading cause of death globally, and current tools are insufficient for many patients.
The featured article underscores the potential of Cardio Diagnostics’ platform to transform cardiovascular care across different settings. For clinicians, tests like Epi+Gen CHD and PrecisionCHD can offer actionable information for individual patients. For population health managers, HeartRisk can identify at-risk groups. For biopharma companies, CardioInnovate360 can support drug development and clinical trials. This multi-pronged approach highlights the broad implications of the company’s technology.
Forward-looking statements in the article remind investors that actual results may differ due to risks and uncertainties. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
